← Search & browse all drugs
RESPIRATORY SYSTEM › NASAL PREPARATIONS › DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE › Corticosteroids
fluticasone furoate
R01AD12
Forms & Strengths
- Nasal spray: 27.5 mcg per actuation
- Inhalation powder (DPI): 50 mcg, 100 mcg, 200 mcg per blister
Adult Dosing
- Allergic rhinitis (nasal): 2 sprays (110 mcg) in each nostril once daily
- Asthma (inhalation): 100 mcg to 200 mcg once daily in the evening via Ellipta inhaler
Pediatric Dosing
- Allergic rhinitis (children 2-11 years): 1 spray (27.5 mcg) in each nostril once daily
- Allergic rhinitis (adolescents >=12 years): 2 sprays (110 mcg) in each nostril once daily
- Asthma (children >=12 years): 100 mcg once daily via Ellipta inhaler
Indications
- Treatment of symptoms of seasonal and perennial allergic rhinitis
- Maintenance treatment of asthma in patients aged 12 years and older
Mechanism of Action
- Synthetic trifluorinated corticosteroid with potent glucocorticoid activity
- Binds to high-affinity glucocorticoid receptors, suppressing multiple inflammatory pathways and cytokine production
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures
- Hypersensitivity to fluticasone furoate or any excipients
Adverse Reactions
- Epistaxis
- Nasal ulceration
- Nasopharyngitis
- Headache
- Oral candidiasis (inhalation form)
- Hypothalamic-pituitary-adrenal (HPA) axis suppression (high doses/long-term)
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) significantly increase systemic exposure and risk of systemic corticosteroid effects
- CYP3A4 inducers may decrease systemic exposure of fluticasone furoate
Curated Content: Needs Vetting Before Put to Clinical Use